MA31999B1 - Proteines de liaison a l'antigene - Google Patents

Proteines de liaison a l'antigene

Info

Publication number
MA31999B1
MA31999B1 MA32987A MA32987A MA31999B1 MA 31999 B1 MA31999 B1 MA 31999B1 MA 32987 A MA32987 A MA 32987A MA 32987 A MA32987 A MA 32987A MA 31999 B1 MA31999 B1 MA 31999B1
Authority
MA
Morocco
Prior art keywords
amyloid
antigen
binding proteins
diseases
methods
Prior art date
Application number
MA32987A
Other languages
Arabic (ar)
English (en)
Inventor
Philippe Marc Louis Alard
Jonathan Henry Ellis
Susannah Karen Ford
Volker Germaschewski
Alan Peter Lewis
Peter Ernest Soden
Pamela Joan Thomas
Trevor Anthony Kenneth Wattam
Ian Richard Catchpole
Gerald Wayne Gough
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40547800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31999(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0724185A external-priority patent/GB0724185D0/en
Priority claimed from GB0806230A external-priority patent/GB0806230D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA31999B1 publication Critical patent/MA31999B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des protéines de liaison à l'antigène qui se lient au peptide ²-amyloïde, en particulier au peptide ²-amyloïde humain; des méthodes utilisant ces protéines de liaison à l'antigène pour traiter des maladies ou des troubles caractérisés par des taux élevés de ²-amyloïde ou des dépôts ²-amyloïdes, notamment la maladie d'alzheimer et des maladies ou des troubles affectant l'sil ou le nerf optique et qui sont caractérisés par des taux élevés de ²-amyloïde ou des dépôts ²-amyloïdes, y compris la dégénérescence maculaire liée à l'âge et des maladies du type glaucome et la formation de cataracte dépendant des protéines ²-amyloïdes; des compositions pharmaceutiques comprenant ces protéines de liaison à l'antigène; et des procédés de fabrication.
MA32987A 2007-12-11 2010-07-05 Proteines de liaison a l'antigene MA31999B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0724185A GB0724185D0 (en) 2007-12-11 2007-12-11 Antibodies
GB0806230A GB0806230D0 (en) 2008-04-04 2008-04-04 Antibodies
US4383908P 2008-04-10 2008-04-10
PCT/EP2008/067138 WO2009074583A1 (fr) 2007-12-11 2008-12-09 Protéines de liaison à l'antigène

Publications (1)

Publication Number Publication Date
MA31999B1 true MA31999B1 (fr) 2011-01-03

Family

ID=40547800

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32987A MA31999B1 (fr) 2007-12-11 2010-07-05 Proteines de liaison a l'antigene

Country Status (24)

Country Link
US (2) US8921523B2 (fr)
EP (1) EP2222705B1 (fr)
JP (2) JP5512537B2 (fr)
KR (2) KR101657637B1 (fr)
CN (1) CN101970484B (fr)
AR (1) AR069610A1 (fr)
AU (1) AU2008334637B2 (fr)
BR (1) BRPI0819916A2 (fr)
CA (1) CA2707859A1 (fr)
CL (1) CL2008003655A1 (fr)
CO (1) CO6280540A2 (fr)
CR (1) CR11561A (fr)
DO (1) DOP2010000170A (fr)
EA (1) EA022913B1 (fr)
ES (1) ES2525704T3 (fr)
IL (1) IL206188A0 (fr)
MA (1) MA31999B1 (fr)
MX (1) MX2010006422A (fr)
NZ (1) NZ586003A (fr)
PE (1) PE20091449A1 (fr)
TW (1) TWI388334B (fr)
UY (1) UY31520A1 (fr)
WO (1) WO2009074583A1 (fr)
ZA (1) ZA201004133B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
JP6081356B2 (ja) 2010-07-30 2017-02-15 エーシー イミューン エス．エー． 安全で機能的なヒト化抗βアミロイド抗体
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
WO2012139069A2 (fr) * 2011-04-07 2012-10-11 Neotope Biosciences Limited Compositions et procédés pour traiter des maladies d'agrégation de protéines impliquant un dépôt d'ic3b
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US9512212B2 (en) * 2012-01-11 2016-12-06 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
FI3019240T3 (fi) 2013-07-09 2024-05-30 Annexon Inc Anti-komplementtitekijä c1q -vasta-aineita ja niiden käyttöjä
AU2014339900B2 (en) * 2013-10-25 2019-10-24 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
DK3105250T3 (da) * 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
BR112017009297B1 (pt) * 2014-11-05 2024-02-15 Annexon, Inc Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
WO2017035401A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amide pour le traitement de troubles immunitaires et inflammatoires
WO2017035405A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amino pour le traitement de troubles immunitaires et inflammatoires
AU2016361517C1 (en) 2015-11-24 2024-06-06 Annexon, Inc. Anti-complement factor C1q Fab fragments and uses thereof
EP3405577B8 (fr) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions et procédés pour inhiber le facteur d
CN105542005B (zh) * 2016-02-03 2018-11-09 大连理工大学 一种抗人淀粉样β肽的纳米抗体及其应用
ES2848206T3 (es) * 2016-10-19 2021-08-05 Alexion Pharma Inc Un método de cuantificar C5 sin unir en una muestra
US11828683B2 (en) * 2016-10-19 2023-11-28 Alexion Pharmaceuticals, Inc. Method of quantitating unbound C5a in a sample
WO2018136827A1 (fr) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Compositions à boucle en épingle à cheveux et procédés pour inhiber le facteur d
WO2018160891A1 (fr) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Composés pharmaceutiques destinés au traitement de troubles médicaux
US20200330592A1 (en) * 2017-10-09 2020-10-22 Keith Black Compositions and methods of treating alzheimer's and other amyloid related diseases
AU2019336238A1 (en) 2018-09-06 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of Complement factor D inhibitors
WO2021183555A1 (fr) * 2020-03-10 2021-09-16 Achillion Pharmaceuticals, Inc. Dépôt de médicament oculaire pour troubles à médiation par le complément
JP2021141861A (ja) * 2020-03-13 2021-09-24 富士フイルム和光純薬株式会社 抗原に対する親和力が向上した抗体のスクリーニング方法および製造方法
CN113929748B (zh) * 2020-07-13 2023-10-20 中国科学技术大学 检测bace1酶活性的试剂盒及用途
CN117131608B (zh) * 2023-10-23 2024-03-15 南京航空航天大学 一种基于最佳环量分布的激励盘方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239797T1 (de) * 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
EP1198251B1 (fr) * 1999-07-23 2006-11-29 Glaxo Group Limited Combinaison d'anticorps anti-ep-cam et d'un agent de chimiotherapie
WO2003076455A2 (fr) 2002-03-05 2003-09-18 Ramot At Tel-Aviv University Ltd. Composition immunisante et procede permettant d'induire une reponse immunitaire contre le site de clivage de $g(b)-secretase
EP1633786A4 (fr) * 2002-10-09 2007-07-25 Rinat Neuroscience Corp Methodes de traitement de la maladie d'alzheimer au moyen d'anticorps diriges contre le peptide g(b)-amyloide et compositions les comprenant
US7575747B2 (en) 2003-02-10 2009-08-18 Applied Molecular Evolution Aβ binding molecules
UY29504A1 (es) * 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
UA94734C2 (ru) * 2006-03-30 2011-06-10 Глаксо Груп Лимитед ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
US20090022728A1 (en) * 2007-03-09 2009-01-22 Rinat Neuroscience Corporation Methods of treating ophthalmic diseases

Also Published As

Publication number Publication date
CN101970484B (zh) 2014-10-01
BRPI0819916A2 (pt) 2015-05-19
EP2222705A1 (fr) 2010-09-01
KR101657637B1 (ko) 2016-09-19
CA2707859A1 (fr) 2009-06-18
NZ586003A (en) 2012-08-31
UY31520A1 (es) 2009-08-03
TWI388334B (zh) 2013-03-11
AR069610A1 (es) 2010-02-03
CL2008003655A1 (es) 2010-04-16
US20110014182A1 (en) 2011-01-20
EA022913B1 (ru) 2016-03-31
DOP2010000170A (es) 2010-08-15
JP2014177462A (ja) 2014-09-25
AU2008334637A1 (en) 2009-06-18
KR20100099277A (ko) 2010-09-10
US20090162358A1 (en) 2009-06-25
ES2525704T3 (es) 2014-12-29
EP2222705B1 (fr) 2014-10-22
WO2009074583A1 (fr) 2009-06-18
MX2010006422A (es) 2010-06-25
JP5512537B2 (ja) 2014-06-04
CR11561A (es) 2010-09-23
PE20091449A1 (es) 2009-10-07
AU2008334637B2 (en) 2014-08-07
CN101970484A (zh) 2011-02-09
ZA201004133B (en) 2011-11-30
CO6280540A2 (es) 2011-05-20
TW200932267A (en) 2009-08-01
KR101629365B1 (ko) 2016-06-14
JP2011506387A (ja) 2011-03-03
US8921523B2 (en) 2014-12-30
KR20150100964A (ko) 2015-09-02
IL206188A0 (en) 2010-12-30
EA201000787A1 (ru) 2010-12-30

Similar Documents

Publication Publication Date Title
MA31999B1 (fr) Proteines de liaison a l'antigene
MA30337B1 (fr) Anticorps
CN107001473A (zh) 抗‑运铁蛋白受体抗体及使用方法
CN107810199A (zh) 具有定制亲和力的抗转铁蛋白受体抗体
ME00502B (me) Antitjela za insulinu sličan receptor faktora i rasta
PH12011502389A1 (en) Monoclonal antibody
UA116614C2 (uk) Антитіло до фактора d і його застосування
CN105358578A (zh) 运铁蛋白受体的抗体及其使用方法
PH12015501207A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
JP2014500886A (ja) 低親和性血液脳関門受容体抗体及びその使用
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
WO2010048332A3 (fr) Composés de traitement de maladies et troubles ophtalmiques
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
CN104245737B (zh) 抗adamts‑5抗体，其衍生物和用途
EP2213684A3 (fr) Anticorps nogo-a pour le traitement de la maladie d'Alzheimer
CN107207591A (zh) 血脑屏障受体抗体及使用方法
MA47392B1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MA53765A1 (fr) Tubulysines et conjugués tubulysines-protéines
EA201100462A1 (ru) Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств
TW202035442A (zh) 經修飾之抗體Fc及其使用方法
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
DE602004010314D1 (de) Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitoren
US20130149237A1 (en) Delivery system for diagnostic and therapeutic agents
MA58646A1 (fr) Tubulysines et conjugués tubulysines-protéines